Akero Q1 2024 cash $903.7M; Phase 2b HARMONY week 96 fibrosis improvement 75% for 50mg EFX

Akero Therapeutics, Inc.

2024-Q1 EPS reported -$0.90

Cash, equivalents and short-term marketable securities $903.7M as of March 31, 2024; March equity offering raised ~$366.9M gross.
Phase 2b HARMONY Week 96: 75% (50mg) and 46% (28mg) achieved ≥1-stage fibrosis improvement without MASH worsening vs 24% placebo (p<0.001 and p=0.07).
36% (50mg) and 31% (28mg) showed 2-stage fibrosis improvement vs 3% placebo (p<0.01).
Total operating expenses $60.0M vs $28.8M YoY on increased R&D for Phase 3 studies.
Phase 3 SYNCHRONY Histology and Real-World enrolling; Outcomes trial on track to start Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Akero Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 10, 2024, Akero Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1049 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-135733

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.